Hamlet Biopharma AB has announced the presentation of new preclinical-stage molecules that have originated from its long-term collaboration with Lund University and Linnane Pharma AB with the aim of treating bacterial infections by targeting the disease response of the host rather than the pathogen itself.
Myocardial ischemia-reperfusion (MI/R) injury is a major contributor to heart failure. The long noncoding RNA (lncRNA) myocardial infarction-associated transcript (MIAT) has been shown to worsen cardiac damage during ischemia, making it a promising target for RNA interference.
CSPC Pharmaceutical Group Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with SYH-2070 injection, a double-stranded small interfering RNA (siRNA) drug for the treatment of hypertriglyceridemia or mixed hyperlipidemia.
Coronary artery bypass graft (CABG) surgery remains the gold standard treatment for patients with severe atherosclerosis, but the long-term failure of the grafted veins is a persistent challenge. Excessive vascular smooth muscle cell (vSMC) proliferation in the grafted tissue, promoted by the increased exposure of vSMCs to pro-inflammatory mediators and cytokines, is a key driver of late CABG failure. A team of researchers from the University of Edinburgh and collaborators previously identified a human-specific long noncoding RNA, named SMILR, that is enriched in vSMC and promotes its proliferation.
Mabwell Bioscience Co. Ltd. and Aditum Bio Management Co. LLC announced, in after-market hours Sept. 17, an agreement to forge a new company called Kalexo Bio Inc. and load the biotech with a preclinical dyslipidemia asset via a potential $1 billion global license deal.
Mabwell Bioscience Co. Ltd. and Aditum Bio Management Co. LLC announced, in after-market hours Sept. 17, an agreement to forge a new company called Kalexo Bio Inc. and load the biotech with a preclinical dyslipidemia asset via a potential $1 billion global license deal.
Mabwell (Shanghai) Bioscience Co. Ltd. and Aditum Bio Management Company LLC have announced the launch of Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141.
Rona Therapeutics Co. Ltd. has announced an IND filing with the Australian Human Research Ethics Committee (HREC) for RN-3161 for obesity. RN-3161, a novel siRNA developed through Rona’s proprietary GAIA platform, targets INHBE to reduce fat while preserving lean mass.
Argo Biopharmaceutical Co. Ltd. and its RNAi work drew Novartis AG back to the table for a third time, as the companies entered a potential $5.2 billion deal involving cardiovascular-focused assets, including a right to first negotiation for BW-00112, an angiopoietin-like protein 3-targeting siRNA in phase II testing in severe hypertriglyceridemia.
Argo Biopharmaceutical Co. Ltd. and its RNAi work drew Novartis AG back to the table for a third time, as the companies entered a potential $5.2 billion deal involving cardiovascular-focused assets, including a right to first negotiation for BW-00112, an angiopoietin-like protein 3-targeting siRNA in phase II testing in severe hypertriglyceridemia.
